Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CD20/anti-CD3/anti-CD8 trispecific antibody AZD5492

A trispecific immunoglobulin G (IgG)-like T-cell engaging (TCE) antibody targeting the tumor-associated antigen (TAA) CD20 and the T-cell surface antigens CD3 and CD8, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD20/anti-CD3/anti-CD8 trispecific antibody AZD5492 targets and binds to CD20 on CD20-expressing tumor B-cell, and the CD3 and CD8 antigens on CD8-positive T lymphocytes. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against CD20-expressing tumor cells. CD20, a B-cell-specific cell surface antigen, is overexpressed in B-cell lineage malignancies.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:CD8/TCR-based CD20-targeting T-cell engaging antibody AZD5492
T-cell engager AZD5492
T-cell engaging antibody AZD5492
TCE AZD5492
triple-specific antibody AZD5492
Code name:AZD 5492
AZD-5492
AZD5492
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search